Adlai Nortye wins FDA IND clearance for AN4035 ADC trial expansion to US
ANL•First patient dosed in Australia
First patient dosed in Australia in the global Phase I study for CEACAM5-enriched, RAS-addicted solid tumors.
FDA clears AN4035 IND for U.S. trial expansion
Adlai Nortye received U.S. FDA IND clearance for AN4035, enabling its Phase I trial to expand into the U.S.
